Financial Engines Advisors L.L.C. Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Financial Engines Advisors L.L.C. purchased a new position in Grifols, S.A. (NASDAQ:GRFS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 48,136 shares of the biotechnology company’s stock, valued at approximately $358,000.

Several other institutional investors also recently modified their holdings of GRFS. Whitebox Advisors LLC raised its stake in Grifols by 56.2% during the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after buying an additional 1,519,093 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Grifols by 144.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after purchasing an additional 1,181,959 shares during the last quarter. Brandes Investment Partners LP boosted its stake in Grifols by 3.0% in the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company’s stock worth $152,491,000 after purchasing an additional 592,096 shares in the last quarter. Barclays PLC grew its position in Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock valued at $5,261,000 after purchasing an additional 469,401 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in Grifols during the 3rd quarter valued at about $2,636,000.

Grifols Trading Down 2.0 %

Shares of NASDAQ:GRFS opened at $7.31 on Friday. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96. The stock’s fifty day moving average price is $7.56 and its 200-day moving average price is $8.06. The company has a market cap of $5.03 billion, a P/E ratio of 6.25 and a beta of 0.35. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.